Data presented highlight the potential utility of targeting lysosomal genes to treat neurodegenerative diseases, including Alzheimer’s

提供的数据突出了靶向溶酶体基因治疗神经退行性疾病（包括阿尔茨海默氏病）的潜在效用

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Jaya Biosciences, Inc. (“JayaBio” or “the Company”), a privately held early-stage life-sciences company developing gene therapies to address unmet needs in genetically defined neurodegeneration, presented promising non-clinical data for a novel treatment approach in Alzheimer’s disease at the 23rd Annual Needham Virtual Healthcare Conference.

加利福尼亚州南旧金山，2024年4月9日（环球通讯社）--Jaya Biosciences，Inc.（“JayaBio”或“the Company”），一家私营的早期生命科学公司，开发基因疗法以解决基因定义的神经退行性变中未满足的需求，在第23届Needham虚拟医疗会议上为阿尔茨海默病的新型治疗方法提供了有希望的非临床数据。

JayaBio’s President and CEO, Pawel Krysiak, reviewed the rationale for targeting the autophagy-lysosomal pathway and discussed the Company’s lead program, JB111, including its strong animal proof-of-concept data and near-term development milestones..

JayaBio的总裁兼首席执行官PawelKrysiak回顾了针对自噬-溶酶体途径的基本原理，并讨论了该公司的领先项目JB111，包括其强大的动物概念验证数据和近期发展里程碑。。

“We are grateful for the opportunity to share a new paradigm for the treatment of genetically defined neurodegeneration with the investor community at the 23rd Annual Needham Virtual Healthcare Conference,” said Pawel Krysiak, President and CEO of JayaBio. “The preclinical update we presented demonstrates a tremendous promise of targeting PPT1 haploinsufficiency in Alzheimer’s disease, and with the right funding in place, we could transition this program into the clinic within 3 years.

JayaBio总裁兼首席执行官PawelKrysiak说：“我们很高兴有机会在第23届李约瑟虚拟医疗会议上与投资者分享治疗基因定义神经退行性疾病的新范例。我们介绍的临床前更新显示了针对阿尔茨海默氏病PPT1单一等位基因不足性的巨大希望，如果有适当的资金，我们可以在3年内将该计划转变为诊所。

Given the size of the unmet need and the strong potential of our platform, we hope to attract experienced investors to support JayaBio’s progress and help us develop life-changing therapies for genetically defined neurodegeneration, including Alzheimer’s disease.”.

鉴于未满足需求的规模和我们平台的强大潜力，我们希望吸引有经验的投资者支持JayaBio的进展，并帮助我们开发改变生命的疗法，治疗遗传定义的神经退行性疾病，包括阿尔茨海默氏病。”。

The following talk was presented at the 23rd Annual Needham Virtual Healthcare Conference:

以下演讲是在第23届李约瑟虚拟医疗会议上发表的：

Title: Jaya Biosciences: New Paradigm for Genetically-Defined Neurodegenerative Diseases

标题：Jaya Biosciences：遗传定义的神经退行性疾病的新范例

Date and Time: Mon, Apr 8 at 11:45-12:25 PM

日期和时间：4月8日星期一下午11:45-12:25

Session: Track 3

课程：第三轨道

Presenter (virtual): Pawel Krysiak, President & CEO, Jaya Biosciences Inc.

主持人（虚拟）：Jaya Biosciences Inc.总裁兼首席执行官Pawel Krysiak。

Needham Moderator: James Diamond

李约瑟主持人：詹姆斯·戴蒙德

About The 23rd Annual Needham Virtual Healthcare Conference

关于第23届李约瑟虚拟医疗年会

This fully virtual conference features fireside chats and presentations from leading public and private companies in the Biopharma, Medtech, Diagnostics and Digital Health sectors as well as thematic panel discussions.

这次完全虚拟的会议的特点是炉边聊天和来自生物制药、医疗技术、诊断和数字健康领域领先的公共和私营公司的演讲，以及专题小组讨论。

About JB111

关于JB111

JB111, Jaya Biosciences’ lead therapy, is an experimental CNS-directed AAV9-mediated PPT1 gene therapy currently being developed for neurodegeneration associated with PPT1 haploinsufficiency (carrier status for loss-of-function mutations in palmitoyl protein thioesterase-1 gene or PPT1 heterozygosity).

JB111是Jaya Biosciences的先导疗法，是一种实验性的中枢神经系统指导的AAV9介导的PPT1基因疗法，目前正在开发用于与PPT1单倍剂量不足相关的神经退行性疾病（棕榈酰蛋白硫酯酶-1基因或PPT1杂合性功能丧失突变的携带者状态）。

JB111 showed very promising results in the animal model of PPT1-associated Alzheimer’s disease (5XFAD mouse harboring PPT1 heterozygous allele). Single intracerebroventricular (ICV) injection of JB111 resulted in a significantly increased life span and improved cognitive performance..

JB111在PPT1相关阿尔茨海默氏病（携带PPT1杂合等位基因的5XFAD小鼠）的动物模型中显示出非常有希望的结果。单次脑室内（ICV）注射JB111可显着延长寿命并改善认知能力。。

About Jaya Biosciences, Inc.

关于Jaya Biosciences，Inc。

Jaya Biosciences is a privately held pre-clinical stage life sciences company developing CNS-directed gene therapies for genetically defined neurodegenerative diseases, including Alzheimer's, Parkinson’s, and frontotemporal dementia. Jaya’s platform is based on the groundbreaking discovery that carriers of loss-of-function mutations in genes for lysosomal enzymes have an increased risk of neurodegeneration, including early onset of symptoms.

Jaya Biosciences是一家私营的临床前阶段生命科学公司，开发针对遗传定义的神经退行性疾病（包括阿尔茨海默氏症，帕金森氏症和额颞叶痴呆）的中枢神经系统定向基因疗法。Jaya的平台是基于一个开创性的发现，即溶酶体酶基因功能丧失突变的携带者增加了神经退行性疾病的风险，包括症状的早期发作。

Jaya Biosciences’ team, proven in drug development and commercialization of lysosomal targets and gene therapies, is dedicated to addressing unmet needs in neurodegeneration and adding value to patient and medical communities worldwide. Jaya’s mission is to fulfill a promise of victory over neurodegeneration by identifying and targeting the relevant pathways involved in the etiology of these debilitating diseases.

Jaya Biosciences的团队在溶酶体靶标和基因疗法的药物开发和商业化方面得到了证实，致力于解决神经退行性疾病中未满足的需求，并为全球患者和医学界增加价值。Jaya的使命是通过识别和靶向与这些衰弱性疾病的病因有关的途径，实现战胜神经退行性疾病的承诺。

For more information, please visit www.jayabio.com.

有关更多信息，请访问www.jayabio.com。

Investor/Media Contact:

投资者/媒体联系人：

Jaya Biosciences Inc.

Jaya生物科学公司。

info@jayabio.com

info@jayabio.com